Last reviewed · How we verify
Recombinant Chimeric Monoclonal Antibody — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Recombinant Chimeric Monoclonal Antibody (Recombinant Chimeric Monoclonal Antibody) — ICOS Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant Chimeric Monoclonal Antibody TARGET | Recombinant Chimeric Monoclonal Antibody | ICOS Corporation | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant Chimeric Monoclonal Antibody CI watch — RSS
- Recombinant Chimeric Monoclonal Antibody CI watch — Atom
- Recombinant Chimeric Monoclonal Antibody CI watch — JSON
- Recombinant Chimeric Monoclonal Antibody alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant Chimeric Monoclonal Antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-chimeric-monoclonal-antibody. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab